SCHEMBL723485

SCHEMBL723485

COC(=O)c1cc(OCC2CC2)cc(-c2ccnc3cc(-c4cc(OC)c(OC)c(OC)c4)oc23)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 2/20 0.39
BRD4 O60885 3/20 0.36
PDE4D Q08499 4/20 0.35
PDE4A P27815 3/20 0.35
PDE3B Q13370 3/20 0.35
PDE3A Q14432 3/20 0.35
SYK P43405 2/20 0.35
FYN P06241 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
CYP2C9 P11712 1/20 0.34
JAK2 O60674 2/20 0.34
JAK1 P23458 2/20 0.34
TYK2 P29597 2/20 0.34
JAK3 P52333 2/20 0.34
P2RX3 P56373 1/20 0.33
P2RX2 Q9UBL9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725258 0.92 PDE4C (0.40) PDE4CBRD4PDE4DPDE4APDE3B
SCHEMBL16626217 0.86 CNR1 (0.39) PDE4CBRD4SYKFYN
SCHEMBL723418 0.86 CNR1 (0.39) PDE4CBRD4SYKFYN
SCHEMBL724951 0.85 PDE4C (0.42) PDE4CBRD4ALDH1A1MAPTCYP2C9
SCHEMBL723670 0.84 PDE4C (0.41) PDE4CBRD4ALDH1A1MAPTCYP2C9
SCHEMBL721628 0.83 PDE4C (0.42) PDE4CBRD4FYNALDH1A1JAK2
SCHEMBL721518 0.81 PDE4C (0.43) PDE4CBRD4FYNALDH1A1MAPT
SCHEMBL10268115 0.80 PDE4C (0.45) PDE4CBRD4ALDH1A1
SCHEMBL724085 0.80 PDE4C (0.45) PDE4CBRD4FYNJAK2JAK1
SCHEMBL723532 0.80 PDE4C (0.40) PDE4CBRD4ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885BRD4 1150/4885PDE4D 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.